Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

BOULDER -- Clovis Oncology (NASDAQ: CLVS) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance... Read More

Tuesday October 10, 2017 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey, FDA

Clovis Oncology's rucaparib ovarian cancer drug granted FDA Breakthrough Therapy designation

Clovis Oncology's rucaparib ovarian cancer drug granted FDA Breakthrough Therapy designation

BOULDER Clovis Oncology Inc. (NASDAQ: CLVS) announced the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the companys investigational agent rucaparib as... Read More

By: InnovatioNews Tuesday April 7, 2015 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey

Investors announced for 2013 Rocky Mountain Life Science Investor and Partnering Conference

Investors announced for 2013 Rocky Mountain Life Science Investor and Partnering Conference

DENVER - More than 35 leading investors and strategic partners from across the U.S. will be attending the Rocky Mountain Life Science Investor and Partnering Conference in Denver on Sept. 19. ... Read More

By: InnovatioNews Wednesday September 11, 2013 0 comments Tags: Denver, Kyle Lefkoff, Patrick J. Mahaffey, Ron Squarer

Clovis Oncology and Foundation Medicine announce diagnostic collaboration

Clovis Oncology and Foundation Medicine announce diagnostic collaboration

BOULDER - Clovis Oncology Inc. (Nasdaq: CLVS) and Foundation Medicine Inc. today announced they have entered into a collaboration aimed at developing an in-vitro diagnostic (IVD) to identify... Read More

By: Steve Monday August 6, 2012 0 comments Tags: Clovis Oncology, Foundation Medicine, Michael J. Pellini, Patrick J. Mahaffey, Rucaparib